Research & Development
Novel, human genetic-based discoveries
Developing new treatments for patients is challenging, with just one in ten drugs entering clinical trials being approved. However, drugs supported by human genetic evidence are over twice as likely to succeed in clinical trials, making it critical for modern drug discovery. We leverage unique data from our genomic partnerships around the world to identify first-in-class targets with strong genetic support that can rapidly progress to the clinic and provide life-saving therapies to patients.
![A close up of hands with a blood test being administered.](https://variant-bio.transforms.svdcdn.com/staging/default/blood-test.jpg?w=980&h=735&q=82&auto=format&fit=crop&dm=1684270480&s=d36d9b39e7871902242e31528194dd87 980w, https://variant-bio.transforms.svdcdn.com/staging/default/blood-test.jpg?w=768&h=576&q=82&auto=format&fit=crop&dm=1684270480&s=7ec1fca470cea7949ceb47b5d6e217ea 768w, https://variant-bio.transforms.svdcdn.com/staging/default/blood-test.jpg?w=640&h=480&q=82&auto=format&fit=crop&dm=1684270480&s=717db6eb51e60d6941a7b4646d04ed94 640w, https://variant-bio.transforms.svdcdn.com/staging/default/blood-test.jpg?w=480&h=360&q=82&auto=format&fit=crop&dm=1684270480&s=583e801cb31114aa88370dafe44070ed 480w)
Human genetic validation is the foundation of all our programs
Multi-omic data are integrated using the VB-Inference platform to identify causal genes and establish directionality so that clear therapeutic hypotheses can be formed. Targets with converging genetic evidence across cohorts and ancestries are prioritized. Before initiating drug discovery, we validate therapeutic hypotheses using a combination of in vitro and in vivo models with strong links to disease-relevant mechanisms. We advance programs that are druggable by standard modalities and have existing tool compounds, or where our novel genetic insights identify in-licensing opportunities for clinical stage assets.
![A scientist standing in a lab coat and face mask, operating lab equipment on a table.](https://variant-bio.transforms.svdcdn.com/staging/default/lab-equipment.jpg?w=980&h=735&q=82&auto=format&fit=crop&dm=1684270542&s=cdb5121fd5e2c759f906167e88b0147b 980w, https://variant-bio.transforms.svdcdn.com/staging/default/lab-equipment.jpg?w=768&h=576&q=82&auto=format&fit=crop&dm=1684270542&s=ef7085b121089264762c3c154737ab91 768w, https://variant-bio.transforms.svdcdn.com/staging/default/lab-equipment.jpg?w=640&h=480&q=82&auto=format&fit=crop&dm=1684270542&s=73ecd03674d997f81dfef5b44159abe4 640w, https://variant-bio.transforms.svdcdn.com/staging/default/lab-equipment.jpg?w=480&h=360&q=82&auto=format&fit=crop&dm=1684270542&s=bb8843490f3902ca1d651f13f9482d8f 480w)
Our approach to research
Our growing R&D team includes industry-experienced biologists and chemists with track records of success in producing clinical stage molecules (both small molecules and biologics). Our focal point is a new state-of-the-art suite of research labs – equipped with the latest instrumentation. Capabilities encompass: functional genomics, molecular biology, biochemistry, cell biology, pharmacology, medicinal chemistry, analytical chemistry, drug metabolism, and pharmacokinetics.